|
ADA 2006, Washington
WCC 2006, Barcelona
EASD 2006, Copenhagen/Malmoe
AHA 2006, Chicago
IDF 2006, Cape Town
ACC 2007, New Orleans
ADA 2007, Chicago
EASD 2007, Amsterdam
ADA 2008, San Francisco
ADA 2006, Washington
WCC 2006, Barcelona
EASD 2006, Copenhagen/Malmoe
- Diamant, Schindhelm, Heine. Long-term treatment with pioglitazone improves markers of liver function in patients with type 2 diabetes: Results from PROactive. Oral presentation.
- Wilcox. An analysis from PROactive on the effects of pioglitazone on major adverse cardiovascular events (MACE) and myocardial infarction. Oral presentation.
- Spanheimer, Tan, Yates. The effects of long-term pioglitazone therapy on lipid profiles in high-risk type 2 diabetes patients: Results from PROactive. Oral presentation.
- Charbonnel, Scheen. Long-term glycaemic effects of pioglitazone in triple oral therapy: Results from PROactive. Poster presentation.
- Schmitz, Scheen, Charbonnel. Pioglitazone reduces insulin requirements and improves glycaemic control in insulin-treated patients with type 2 diabetes: Results from PROactive. Poster presentation.
- Erdmann, Charbonnel, Dormandy, Yates, Wilcox, Massi-Benedetti. Pioglitazone treatment in patients with type 2 diabetes and a history of MI: Subgroup analyses from PROactive stratified by gender, age, and duration of diabetes. Poster presentation.
Please click here to view the poster in PDF format.
- Dormandy J, Bousser M-G, Wilcox R. Pioglitazone in patients with or without a history of stroke: Results from PROactive. Oral presentation.
Please click here to view the slide set.
These data have now been published.
Please click here to download the paper.
AHA 2006, Chicago
IDF 2006, Cape Town
ACC 2007, New Orleans
- Erdmann, Wilcox, Perez, Yates, Spanheimer, Dormandy. Mortality After Serious Heart Failure: Results From PROactive. These data have now been published.
Click here to download the paper.
ADA 2007, Chicago
- Spanheimer, Erdmann, Yates. Hospitalizations for serious adverse events in a high-risk type 2 diabetes patients treated with pioglitazone for 3-years: Results From PROactive
- Erdmann, Schneider, Yates. Effects of pioglitazone in patients with type 2 diabetes and reduced glomerular filtration rate: an analysis from PROactive
These data have now been published.
- Schneider, Erdmann, Yates. The relationship between renal dysfunction and major cardiovascular outcomes in patients with diabetes: experience from PROactive
These data have now been published.
- Spanheimer, Tan, Yates, Charbonnel, Ferrannini. Effects of long-term treatment with pioglitazone on lipid levels in patients receiving statin therapy at baseline in the PROactive study
These data have now been published.
- Palmer, Minshall, Roze, Valentine, Foos, Silberman. Long-Term CEA on Actos™ for the USA from PROactive
These data have now been published.
- Massi-Benedetti, Valentine, Goodall, Foos, Palmer, Huebner, Luebben, Pang. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing therapies for Germany using the CORE Diabetes Model based on PROactive
These data have now been published
EASD 2007, Amsterdam
- Brandle, Valentine, Goodall, Dumont, Pang, Massi Benedetti. Cost-effectiveness of pioglitazone in type 2 diabetes in Switzerland based on the PROactive study
These data have now been published
ADA 2008, San Fransisco
- Schernthaner, Charbonnel, Betteridge, Ferrannini, Erdmann. Impact of the metabolic syndrome on cardiovascular outcomes in type 2 diabetic patients in PROactive. Poster presentation.
- Spanheimer, Charbonnel, Perez, Kupfer, Erdmann. Pioglitazone and risk of cardiovascular ischemic events in patients with type 2 diabetes mellitus receiving concomitant treatment with nitrates, ACE/ARBs, or insulin. Oral presentation.
- Dormandy, Betteridge, Schernthaner, Pirags, Norgren. Impact of peripheral arterial disease in patients with diabetes — Results from PROactive. Oral presentation.
These data have now been published
|
